DIANTHUS THERAPEUTICS INC (DNTH) Stock News

USA - Nasdaq - NASDAQ:DNTH - US2528281080 - Common Stock

43.15 USD

-0.45 (-1.03%)

Last: 12/9/2025, 3:11:50 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

DNTH Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference

a month ago - By: Zacks Investment Research - Mentions: LXRX

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

3 months ago - By: Benzinga

Analyst Expectations For Dianthus Therapeutics's Future

a month ago - By: Zacks Investment Research - Mentions: DAWN

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics to Participate in Four Investor Conferences During November

a month ago - By: Zacks Investment Research - Mentions: CYTK

Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy?

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

4 months ago - By: The Motley Fool

Dianthus (DNTH) Q2 Loss Widens 80%

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

3 months ago - By: Benzinga - Mentions: APP ADBE AI GM ...

General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday

3 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

3 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

3 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

3 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

3 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

3 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

3 months ago - By: Investor's Business Daily - Mentions: ARGX AZN SNY

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again

3 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

3 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

3 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

4 months ago - By: Toi Management, LLC - Mentions: TOI

The Oncology Institute Announces Changes to Board of Directors

4 months ago - By: Zacks Investment Research - Mentions: CVAC

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

4 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

4 months ago - By: Zacks Investment Research - Mentions: INO

Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline